Recent advances of natural and bioengineered extracellular vesicles and their application in vascular regeneration
Source abstract
Abstract
Abstract The progression of cardiovascular diseases such as atherosclerosis and myocardial infarction leads to serious vascular injury, highlighting the urgent need for targeted regenerative therapy. Extracellular vesicles (EVs) composed of a lipid bilayer containing nuclear and cytosolic materials are relevant to the progression of cardiovascular diseases. Moreover, EVs can deliver bioactive cargo in pathological cardiovascular and regulate the biological function of recipient cells, such as inflammation, proliferation, angiogenesis and polarization. However, because the targeting and bioactivity of natural EVs are subject to several limitations, bioengineered EVs have achieved wide advancements in biomedicine. Bioengineered EVs involve three main ways to acquire including (i) modification of the EVs after isolation; (ii) modification of producer cells before EVs’ isolation; (iii) synthesize EVs using natural or modified cell membranes, and encapsulating drugs or bioactive molecules into EVs. In this review, we first summarize the cardiovascular injury-related disease and describe the role of different cells and EVs in vascular regeneration. We also discuss the application of bioengineered EVs from different producer cells to cardiovascular diseases. Finally, we summarize the surface modification on EVs which can specifically target abnormal cells in injured vascular.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · Electrospun Nanofibers in Biomedical Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, Bioengineering Modern Life Science Experiment Teaching Center of Bioengineering College, Chongqing University , Chongqing 400030, China
Department of Pathology, Guizhou Provincial People’s Hospital , Guiyang 550002, China
Funding
National Natural Science Foundation of China
References (100+)
Show source-provided references
1. Mechanisms, consequences, and prevention of coronary graft failure10.1161/CIRCULATIONAHA.117.027597 ↗
2. Biological responses in stented arteries10.1093/cvr/cvt115 ↗
3. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine10.1038/288373a0 ↗
4. Inflammation in peripheral artery disease10.1161/CIRCULATIONAHA.109.918417 ↗
5. Safety and efficacy of statin therapy10.1038/s41569-018-0098-5 ↗
6. Oral anticoagulants in the management of venous thromboembolism10.1038/nrcardio.2013.73 ↗
7. Exosomes and exosome-inspired vesicles for targeted drug delivery10.3390/pharmaceutics10040218 ↗
8. Membrane vesicles as conveyors of immune responses10.1038/nri2567 ↗
9. Extracellular vesicles as drug delivery systems: lessons from the liposome field10.1016/j.jconrel.2014.07.049 ↗
10. The transport mechanism of extracellular vesicles at the blood–brain barrier10.2174/1381612823666170913164738 ↗
11. M2 macrophage-derived exosomes promote the c-KIT phenotype of vascular smooth muscle cells during vascular tissue repair after intravascular stent implantation10.7150/thno.46143 ↗
12. Model construction and numerical simulation of arterial remodeling after stent implantation with variations of cell concentration10.1016/j.medntd.2022.100144 ↗
13. Anti-Sca-1 antibody-functionalized vascular grafts improve vascular regeneration via selective capture of endogenous vascular stem/progenitor cells10.1016/j.bioactmat.2022.03.007 ↗
14. Exosomal microRNA-98-5p from hypoxic bone marrow mesenchymal stem cells inhibits myocardial ischemia–reperfusion injury by reducing TLR4 and activating the PI3K/Akt signaling pathway10.1016/j.intimp.2021.107592 ↗
15. Extracellular vesicles derived from Krüppel-Like factor 2-overexpressing endothelial cells attenuate myocardial ischemia–reperfusion injury by preventing Ly6C(high) monocyte recruitment10.7150/thno.45459 ↗
16. Exosomes from miRNA-126-modified endothelial progenitor cells alleviate brain injury and promote functional recovery after stroke10.1111/cns.13455 ↗
17. Endothelial progenitor cell-derived exosomes facilitate vascular endothelial cell repair through shuttling miR-21-5p to modulate Thrombospondin-1 expression10.1042/CS20190188 ↗
18. M1-like macrophage-derived exosomes suppress angiogenesis and exacerbate cardiac dysfunction in a myocardial infarction microenvironment10.1007/s00395-020-0781-7 ↗
19. M2 macrophage-derived exosomes promote angiogenesis and growth of pancreatic ductal adenocarcinoma by targeting E2F210.1016/j.ymthe.2020.11.024 ↗
20. Exosomes secreted by macrophages upon copper ion stimulation can promote angiogenesis10.1016/j.msec.2021.111981 ↗
21. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs10.1038/ncb2441 ↗
22. Exosomal Notch3 from high glucose-stimulated endothelial cells regulates vascular smooth muscle cells calcification/aging10.1016/j.lfs.2019.116582 ↗
23. Macrophage exosomes resolve atherosclerosis by regulating hematopoiesis and inflammation via MicroRNA cargo10.1016/j.celrep.2020.107881 ↗
24. Extracellular vesicles secreted by atherogenic macrophages transfer MicroRNA to inhibit cell migration10.1161/ATVBAHA.117.309795 ↗
25. Exosomes from nicotine-stimulated macrophages accelerate atherosclerosis through miR-21-3p/PTEN-mediated VSMC migration and proliferation10.7150/thno.37357 ↗
26. Exosomes derived from M1 macrophages aggravate neointimal hyperplasia following carotid artery injuries in mice through miR-222/CDKN1B/CDKN1C pathway10.1038/s41419-019-1667-1 ↗
27. Endothelial functions10.1161/ATVBAHA.117.309813 ↗
28. Differential contribution of Nox1, Nox2 and Nox4 to kidney vascular oxidative stress and endothelial dysfunction in obesity10.1016/j.redox.2019.101330 ↗
29. Cardiovascular remodelling in coronary artery disease and heart failure10.1016/S0140-6736(14)60107-0 ↗
30. Endothelial regeneration of large vessels is a biphasic process driven by local cells with distinct proliferative capacities10.1016/j.stem.2018.07.011 ↗
31. Resident endothelial cells surrounding damaged arterial endothelium reendothelialize the lesion10.1161/ATVBAHA.110.207365 ↗
32. Vascular repair by endothelial progenitor cells10.1093/cvr/cvn081 ↗
33. Exogenous bone marrow derived-putative endothelial progenitor cells attenuate ischemia reperfusion-induced vascular injury and renal fibrosis in mice dependent on pericytes10.7150/thno.48562 ↗
34. Interleukin-10 deficiency alters endothelial progenitor cell-derived exosome reparative effect on myocardial repair via integrin-linked kinase enrichment10.1161/CIRCRESAHA.119.315829 ↗
35. Endothelial and cardiac progenitor cells for cardiovascular repair: a controversial paradigm in cell therapy10.1016/j.pharmthera.2017.08.004 ↗
36. Angiogenic properties of concentrated growth factors (CGFs): the role of soluble factors and cellular components10.3390/pharmaceutics13050635 ↗
37. Angiogenesis-related genes in endothelial progenitor cells may be involved in sickle cell stroke10.1161/JAHA.119.014143 ↗
38. Interleukin-1β augments the angiogenesis of endothelial progenitor cells in an NF-κB/CXCR7-dependent manner10.1111/jcmm.15220 ↗
39. CD157 marks tissue-resident endothelial stem cells with homeostatic and regenerative properties10.1016/j.stem.2018.01.010 ↗
40. Exosomes from endothelial progenitor cells improve the outcome of a murine model of sepsis10.1016/j.ymthe.2018.02.020 ↗
41. miR-137 boosts the neuroprotective effect of endothelial progenitor cell-derived exosomes in oxyhemoglobin-treated SH-SY5Y cells partially via COX2/PGE2 pathway10.1186/s13287-020-01836-y ↗
42. Cardiac myofibroblast engulfment of dead cells facilitates recovery after myocardial infarction10.1172/JCI83822 ↗
43. Endothelial to mesenchymal transition is common in atherosclerotic lesions and is associated with plaque instability10.1038/ncomms11853 ↗
44. Lactic acid-mediated endothelial to mesenchymal transition through TGF-β1 contributes to in-stent stenosis in poly-L-lactic acid stent10.1016/j.ijbiomac.2019.11.136 ↗
45. Metabolism of vascular smooth muscle cells in vascular diseases10.1152/ajpheart.00220.2020 ↗
46. Cellular stiffness as a novel stemness marker in the corneal limbus10.1016/j.bpj.2016.09.005 ↗
47. Vazquez-Padron RI. c-Kit modifies the inflammatory status of smooth muscle cells10.7717/peerj.3418 ↗
48. Current understanding of intimal hyperplasia and effect of compliance in synthetic small diameter vascular grafts10.1039/D0BM00226G ↗
49. Matrix stiffness regulates SMC functions via TGF-beta signaling pathway10.1016/j.biomaterials.2019.119407 ↗
50. Engineered fibroblast extracellular vesicles attenuate pulmonary inflammation and fibrosis in bleomycin-induced lung injury10.3389/fcell.2021.733158 ↗
51. Exosomes as intercellular messengers in hypertension10.3390/ijms222111685 ↗
52. Nonresolving inflammation10.1016/j.cell.2010.02.029 ↗
53. Redox and Src family kinase signaling control leukocyte wound attraction and neutrophil reverse migration10.1083/jcb.201408090 ↗
54. Nanoparticles retard immune cells recruitment in vivo by inhibiting chemokine expression10.1016/j.biomaterials.2020.120392 ↗
55. Macrophages in tissue repair, regeneration, and fibrosis10.1016/j.immuni.2016.02.015 ↗
56. CD163+ macrophages promote angiogenesis and vascular permeability accompanied by inflammation in atherosclerosis10.1172/JCI93025 ↗
57. Macrophage-derived netrin-1 promotes abdominal aortic aneurysm formation by activating MMP3 in vascular smooth muscle cells10.1038/s41467-018-07495-1 ↗
58. Macrophage polarization: different gene signatures in M1(LPS+) vs. Classically and M2(LPS–) vs. alternatively activated macrophages10.3389/fimmu.2019.01084 ↗
59. Macrophage plasticity, polarization, and function in health and disease10.1002/jcp.26429 ↗
60. TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord10.1016/j.neuron.2014.07.027 ↗
61. Macrophages mediate the repair of brain vascular rupture through direct physical adhesion and mechanical traction10.1016/j.immuni.2016.03.008 ↗
62. Regulation of capillary tubules and lipid formation in vascular endothelial cells and macrophages via extracellular vesicle-mediated microRNA-4306 transfer10.1177/0300060518809255 ↗
63. Carrier-free trehalose-based nanomotors targeting macrophages in inflammatory plaque for treatment of atherosclerosis10.1021/acsnano.1c08391 ↗
64. A nano-emulsion platform functionalized with a fully human scFv-Fc antibody for atheroma targeting: towards a theranostic approach to atherosclerosis10.3390/ijms22105188 ↗
65. Native and bioengineered extracellular vesicles for cardiovascular therapeutics10.1038/s41569-020-0389-5 ↗
66. Elucidation of exosome migration across the blood–brain barrier model in vitro10.1007/s12195-016-0458-3 ↗
67. Biomimetic nanoparticles: preparation, characterization and biomedical applications10.2147/IJN.S9035 ↗
68. The potential of biomimetic nanoparticles for tumor-targeted drug delivery10.2217/nnm-2018-0017 ↗
69. Functional biomimetic nanoparticles for drug delivery and theranostic applications in cancer treatment10.1080/14686996.2018.1528850 ↗
70. Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications10.7150/thno.47841 ↗
71. Biomimetic nanotherapies: red blood cell based core-shell structured nanocomplexes for atherosclerosis management10.1002/advs.201900172 ↗
72. Bioengineered boronic ester modified dextran polymer nanoparticles as reactive oxygen species responsive nanocarrier for ischemic stroke treatment10.1021/acsnano.8b00477 ↗
73. Biomimetic fibrin-targeted and H(2)O(2)-responsive nanocarriers for thrombus therapy10.1016/j.nantod.2020.100986 ↗
74. Bioengineering CXCR4-overexpressing cell membrane functionalized ROS-responsive nanotherapeutics for targeting cerebral ischemia–reperfusion injury10.7150/thno.60785 ↗
75. Molecularly engineered macrophage-derived exosomes with inflammation tropism and intrinsic heme biosynthesis for atherosclerosis treatment10.1002/anie.201913700 ↗
76. Engineered macrophage membrane-enveloped nanomedicine for ameliorating myocardial infarction in a mouse model10.1002/btm2.10197 ↗
77. Treatment of atherosclerosis by macrophage-biomimetic nanoparticles via targeted pharmacotherapy and sequestration of proinflammatory cytokines10.1038/s41467-020-16439-7 ↗
78. Platelet-derived microparticles induce angiogenesis and stimulate post-ischemic revascularization10.1016/j.cardiores.2005.04.007 ↗
79. Nanoparticle biointerfacing by platelet membrane cloaking10.1038/nature15373 ↗
80. Platelet membrane-coated nanoparticle-mediated targeting delivery of rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE(–/–)) mice10.1016/j.nano.2018.08.002 ↗
81. Exosome-eluting stents for vascular healing after ischaemic injury10.1038/s41551-021-00705-0 ↗
82. Exosomes secreted from GATA-4 overexpressing mesenchymal stem cells serve as a reservoir of anti-apoptotic microRNAs for cardioprotection10.1016/j.ijcard.2014.12.043 ↗
83. Bioengineered stem cell membrane functionalized nanocarriers for therapeutic targeting of severe hindlimb ischemia10.1016/j.biomaterials.2018.08.018 ↗
84. Mesenchymal stem cell-derived magnetic extracellular nanovesicles for targeting and treatment of ischemic stroke10.1016/j.biomaterials.2020.119942 ↗
85. The red blood cell and vascular function in health and disease
86. Red blood cell and platelet microparticles in myocardial infarction patients treated with primary angioplasty10.1016/j.ijcard.2014.07.022 ↗
87. Cell membrane camouflaged biomimetic nanoparticles: focusing on tumor theranostics10.1016/j.mtbio.2022.100228 ↗
88. Efficient RNA drug delivery using red blood cell extracellular vesicles10.1038/s41467-018-04791-8 ↗
89. Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application10.1016/j.apsb.2019.01.011 ↗
90. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform10.1073/pnas.1106634108 ↗
91. Cell membrane coating for reducing nanoparticle-induced inflammatory responses to scaffold constructs10.1007/s12274-018-2084-y ↗
92. Enhanced blood suspensibility and Laser-Activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes10.7150/thno.17259 ↗
93. Surface functionalization of gold nanoparticles with red blood cell membranes10.1002/adma.201300638 ↗
94. Extracellular vesicles mediate communication between endothelial and vascular smooth muscle cells10.3390/ijms23010331 ↗
95. Leukocyte count and coronary heart disease: implications for risk assessment10.1016/j.jacc.2004.07.056 ↗
96. Microglial vesicles improve post-stroke recovery by preventing immune cell senescence and favoring oligodendrogenesis10.1016/j.ymthe.2020.12.009 ↗
97. Macrophage membrane camouflaged reactive oxygen species responsive nanomedicine for efficiently inhibiting the vascular intimal hyperplasia10.1186/s12951-021-01119-5 ↗
98. The biogenesis, biological functions, and applications of macrophage-derived exosomes10.3389/fmolb.2021.715461 ↗
99. Roles of exosomes derived from immune cells in cardiovascular diseases10.3389/fimmu.2019.00648 ↗
100. Grapefruit-derived nanovectors use an activated leukocyte trafficking pathway to deliver therapeutic agents to inflammatory tumor sites10.1158/0008-5472.CAN-14-3095 ↗